Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LITE vs NVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

NVS Overall Winner 6-Pillar Tally: LITE 2 – 4 NVS Matrix Metrics: LITE 3 – 7 NVS

As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Lumentum Holdings Inc. (LITE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LITE carries a Unified Composite Score of 58.0/100 (HOLD) at $546.65 (17.9x Forward P/E, 23.4% operating margin), whereas NVS carries 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin).

  • Composite vs. Pillar Nuance: While LITE currently prints a higher short-term Unified Composite Score (58.0/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 23.4% operating margin) and revenue trajectory (+4.7% vs. +136.5% YoY).
  • Technical & Structure Timing Caution: LITE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.9); meanwhile NVS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LITE vs NVS
LITE NASDAQ
Lumentum Holdings Inc. Common Stock
Communications Equipment, Nec
$546.65
-8.38% 1D
Market Cap $53.6B
TTM Revenue $3.74B
Forward P/E 17.9x
Beta / 30D Vol 3.16β · 133% Vol
Unified Composite Score
58.0 / 100 HOLD
Tech 63.0 Fund 57.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.5%), weak momentum, RSI 35
RSI-14: 34.9 · SMA20: $709.10 · SMA50: $860.63
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17

6-Pillar Scorecard Institutional Category Breakdown (LITE 2 – 4 NVS)

Columns: Metric · LITE · NVS
1. Valuation Multiples NVS
Forward P/E 17.9x 16.2x
Trailing P/E 29.3x 30.6x
PEG Ratio 0.63x 3.81x
EV / Revenue 14.4x 7.5x
2. Growth & Scale NVS
Revenue Growth (YoY) +136.5% +4.7%
Earnings Growth (YoY) N/A -68.8%
TTM Revenue (USD) $3.74B $40.5B
Market Cap $53.6B $302.9B
3. Profitability & Quality NVS
Gross Margin 48.0% 75.2%
Operating Margin 23.4% 34.0%
Net Profit Margin -175.8% 17.5%
Return on Equity (ROE) -245.8% 24.3%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $356M $17.0B EBITDA
Cash Flow Margin 9.5% 42.0% EBITDA Mgn
Net Cash / Leverage $158M Net Debt (0.31x D/E) $19.71 Book/Sh · 24.3% ROE
Dividend Yield None (0.00%) 2.96%
5. Options & Positioning LITE
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 76.7% (13th %ile) 16.9% (6th %ile)
Put/Call OI Skew 1.23x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat LITE
OpEx & R&D Intensity 24.6% of Rev ($921M) 41.2% of Rev ($16.7B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat High-Margin Pricing Power Moat
Supply-Chain Role Communication Equipment Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LITE (3) vs NVS (7)
Institutional Metric LITE NVS Criterion Row Edge
Market Capitalization
Scale
$53.6B $302.9B Larger Scale NVS
Trailing P/E Ratio
Valuation
29.3x 30.6x Lower Multiple LITE
Forward P/E Ratio
Valuation
17.9x 16.2x Lower Multiple NVS
Revenue Growth (YoY)
Growth
+136.5% +4.7% Higher Growth LITE
Operating Margin (TTM)
Profitability
23.4% 34.0% Higher Margin NVS
Net Profit Margin
Profitability
-175.8% 17.5% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
-245.8% 24.3% Higher ROE NVS
52-Week Range Position
Momentum
36% ($215–$1,143) 81% ($123–$170) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
3.16β · 133% Vol 0.31β · 27% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
58.0 / 100 (HOLD) 41.5 / 100 (SELL) Higher Composite LITE
Trailing 12M Revenue (USD)
Operating Scale
$3.74B $40.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
48.0% 75.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.63x PEG · 14.4x EV/Rev 3.81x PEG · 7.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$356M ($158M Net Debt (0.31x D/E)) $17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVS +40.95 pp
LITE: -33.67% · NVS: +7.28%
3M Horizon NVS +41.96 pp
LITE: -37.4% · NVS: +4.56%
6M Horizon NVS +46.57 pp
LITE: -38.23% · NVS: +8.34%
1Y Horizon LITE +118.46 pp
LITE: +140.96% · NVS: +22.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LITE vs NVS. Trailing 12-month operating profitability (LITE 23.4% vs NVS 34.0%) and valuation multiples (LITE 17.9x vs NVS 16.2x Forward P/E) are benchmarked directly in Pillar 4 below.

LITE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.74B
Gross Margin48.0%
Op. Margin23.4%
ROE / Fwd P/E-245.8% · 17.9x
NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LITE BREAKDOWN
130d in phase · OBV NEUTRAL
Current IV 76.7%
IV Percentile 13th %ile
Put/Call OI Skew 1.23x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LITE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LITE Moat Profile Concentrated Oligopoly Moat
Communication Equipment Operator
Competes within the Communication Equipment value chain with $53.6B market capitalization and 23.4% operating margin.
OpEx & R&D Reinvestment 24.6% of Rev ($921M)
90D Engineering Disclosures 0 Published · Silicon Photonics
Mapped Supply-Chain Ecosystem (18 partners):
Corning Coherent Sumitomo Electric Industries Furukawa Electric
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published

Investor FAQ LITE vs NVS Key Questions & Quantitative Answers

As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Lumentum Holdings Inc. (LITE) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LITE carries a Unified Composite Score of 58.0/100 (HOLD) at $546.65 (17.9x Forward P/E, 23.4% operating margin), whereas NVS carries 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin). Composite vs. Pillar Nuance: While LITE currently prints a higher short-term Unified Composite Score (58.0/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 23.4% operating margin) and revenue trajectory (+4.7% vs. +136.5% YoY). Technical & Structure Timing Caution: LITE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.9); meanwhile NVS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NVS leads the Growth & Scale pillar: LITE posts +136.5% YoY revenue growth and N/A YoY earnings growth on $3.74B TTM revenue (48.0% gross margin, 23.4% operating margin), compared with NVS at +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin). On trailing 12-month operating scale, LITE generates $3.74B in USD-normalized revenue versus $40.5B for NVS. In operating R&D and SG&A reinvestment, LITE deploys 24.6% of Rev ($921M) (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($16.7B) (0 disclosures) for NVS.

NVS screens cheaper on headline valuation multiples. LITE trades at 17.9x Forward P/E, 29.3x Trailing P/E, 0.63x PEG, and 14.4x EV/Revenue (9.5% FCF margin), whereas NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LITE (-245.8% ROE) versus NVS (24.3% ROE) capital efficiency.

In options market volatility and institutional positioning, LITE carries 76.7% implied volatility (13th %ile, Compressed (<25th %ile)), a 1.23x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.16β · 133% Vol realized risk). By comparison, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.